Report Detail

Pharma & Healthcare Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review

  • RnM3436002
  • |
  • 20 May, 2019
  • |
  • Global
  • |
  • 60 Pages
  • |
  • GlobalData
  • |
  • Pharma & Healthcare

Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Hikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma Pharmaceuticals sells its products through sales and marketing teams and representatives to leading wholesalers, pharmacy chains, governments and hospital purchasing organizations. The company markets its products in the UK, the Middle East and North Africa (MENA) and Europe and Rest of the World (ROW). Hikma Pharmaceuticals is headquartered in London, the UK.

Hikma Pharmaceuticals Plc Key Recent Developments

Mar 13,2019 Hikma delivers strong 2018 results and makes good strategic progress to position for future growth
Mar 12,2019 Hikma board appoints Cynthia Schwalm as director
Nov 30,2018 Hikma demonstrates support for US pharmacists and patient safety

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Table of Contents

    Table of Contents

      List of Tables

        List of Figures

          Section 1 - About the Company

            Hikma Pharmaceuticals Plc - Key Facts

              Hikma Pharmaceuticals Plc - Key Employees

                Hikma Pharmaceuticals Plc - Key Employee Biographies

                  Hikma Pharmaceuticals Plc - Major Products and Services

                    Hikma Pharmaceuticals Plc - History

                      Hikma Pharmaceuticals Plc - Company Statement

                        Hikma Pharmaceuticals Plc - Locations And Subsidiaries

                          Head Office

                            Other Locations & Subsidiaries

                              Joint Venture

                                Section 2 – Company Analysis

                                  Company Overview

                                    Hikma Pharmaceuticals Plc - Business Description

                                      Business Segment: Branded

                                        Overview

                                          Performance

                                            Business Segment: Generics

                                              Overview

                                                Performance

                                                  Business Segment: Injectables

                                                    Overview

                                                      Performance

                                                        Business Segment: Others

                                                          Performance

                                                            Geographical Segment: Europe and Rest of the World

                                                              Performance

                                                                Geographical Segment: Middle East and North Africa

                                                                  Performance

                                                                    Geographical Segment: The UK

                                                                      Performance

                                                                        Geographical Segment: The US

                                                                          Performance

                                                                            R&D Overview

                                                                              Hikma Pharmaceuticals Plc - Corporate Strategy

                                                                                Hikma Pharmaceuticals Plc - SWOT Analysis

                                                                                  SWOT Analysis - Overview

                                                                                    Hikma Pharmaceuticals Plc - Strengths

                                                                                      Hikma Pharmaceuticals Plc - Weaknesses

                                                                                        Hikma Pharmaceuticals Plc - Opportunities

                                                                                          Hikma Pharmaceuticals Plc - Threats

                                                                                            Hikma Pharmaceuticals Plc - Key Competitors

                                                                                              Section 3 – Company Financial Ratios

                                                                                                Financial Ratios - Capital Market Ratios

                                                                                                  Financial Ratios - Annual Ratios

                                                                                                    Performance Chart

                                                                                                      Financial Performance

                                                                                                        Financial Ratios - Interim Ratios

                                                                                                          Financial Ratios - Ratio Charts

                                                                                                            Section 4 – Company’s Lifesciences Financial Deals and Alliances

                                                                                                              Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

                                                                                                                Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

                                                                                                                  Hikma Pharmaceuticals Plc, Recent Deals Summary

                                                                                                                    Section 5 – Company’s Recent Developments

                                                                                                                      Mar 13, 2019: Hikma delivers strong 2018 results and makes good strategic progress to position for future growth

                                                                                                                        Mar 12, 2019: Hikma board appoints Cynthia Schwalm as director

                                                                                                                          Nov 30, 2018: Hikma demonstrates support for US pharmacists and patient safety

                                                                                                                            Nov 09, 2018: Vectura and Hikma to jointly develop generic versions of GSK’s Ellipta

                                                                                                                              Nov 08, 2018: Hikma updates on current trading and raises 2018 guidance

                                                                                                                                Oct 04, 2018: Hikma Pharmaceuticals names Sagar Patel as European Commercial Head for Injectables

                                                                                                                                  Oct 04, 2018: Hikma Appoints Global Head of Intellectual Property and US General Counsel

                                                                                                                                    Aug 16, 2018: Hikma Pharmaceuticals appoints Kristy Ronco executive vice president, sales and marketing, generics

                                                                                                                                      Aug 15, 2018: Hikma Pharmaceuticals: Half-year report

                                                                                                                                        Section 6 – Appendix

                                                                                                                                          Methodology

                                                                                                                                            Ratio Definitions

                                                                                                                                              About GlobalData

                                                                                                                                                Contact Us

                                                                                                                                                  Disclaimer

                                                                                                                                                  Summary:
                                                                                                                                                  Get latest Market Research Reports on Hikma Pharmaceuticals Plc (HIK) . Industry analysis & Market Report on Hikma Pharmaceuticals Plc (HIK) is a syndicated market report, published as Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review. It is complete Research Study and Industry Analysis of Hikma Pharmaceuticals Plc (HIK) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                                  Last updated on

                                                                                                                                                  REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                  Purchase this Report

                                                                                                                                                  $500.00
                                                                                                                                                  $1,000.00
                                                                                                                                                  $1,500.00
                                                                                                                                                  386.50
                                                                                                                                                  773.00
                                                                                                                                                  1,159.50
                                                                                                                                                  465.50
                                                                                                                                                  931.00
                                                                                                                                                  1,396.50
                                                                                                                                                  76,345.00
                                                                                                                                                  152,690.00
                                                                                                                                                  229,035.00
                                                                                                                                                  42,200.00
                                                                                                                                                  84,400.00
                                                                                                                                                  126,600.00
                                                                                                                                                  Credit card Logo

                                                                                                                                                  Related Reports


                                                                                                                                                  Reason to Buy

                                                                                                                                                  Request for Sample of this report